Corona Remedies
Corona Remedies Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Corona Remedies Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Corona Remedies Ltd trades at a P/E of 58.80×.
Valuation
Profitability
Growth
Financial Health
Corona Remedies Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Corona Remedies Ltd, switchable between annual and quarterly views, consolidated or standalone.
Corona Remedies Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹10,602.71 Cr and reported EPS of ₹24.40.
| Period | 2026 |
|---|---|
| Revenue from Operations | 1,403 |
| Other Income | 11 |
| Total Income | 1,414 |
| Cost of Goods Sold (COGS) | 261 |
| Gross Profit | 1,142 |
| +Operating Expenses | 849 |
| EBITDA | 293 |
| +Non-Operating Expenses | 26 |
| Profit Before Tax (PBT) | 240 |
| +Tax Expense | 55 |
| Profit After Tax (PAT) | 185 |
| Earnings Per Share (EPS) | 30.27 |
| Diluted Shares Outstanding (Nos.) | 6 |
| +Additional Disclosures | 1,416 |
| Material Cost % | 7 |
| Employee Cost % | 29 |
| Other Cost % | 32 |
| OPM % | 21 |
| Tax % | 23 |
| Gross Margin % | 0.00 |
| EBITDA Margin % | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Additional Fields | 256 |
Corona Remedies segment analysis: revenue and profit mix.
Disclosed business segments at Corona Remedies with their share of revenue and profit, switchable between consolidated and standalone reporting.
Corona Remedies discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Corona Remedies Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Corona Remedies Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
What you're getting.
No strengths or opportunities on record.
What can break it.
No weaknesses or threats on record.
What would change my mind.
Trim if P/E re-rates above 76. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 23%. The operating engine is no longer compounding capital efficiently.
Corona Remedies Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Corona Remedies Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Corona Remedies Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Corona Remedies Ltd — derived from the live tape, not yesterday's close.
Corona Remedies Ltd last traded at ₹1,728.3 with an intraday range of ₹1,694–₹1,739 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1728.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1836.87 | +108.57 | +6.28% |
| R3 | 1791.87 | +63.57 | +3.68% |
| R2 | 1765.43 | +37.13 | +2.15% |
| R1 | 1746.87 | +18.57 | +1.07% |
| PIVOT | 1720.43 | -7.87 | -0.46% |
| CURRENT | 1728.30 | — | — |
| S1 | 1611.87 | -116.43 | -6.74% |
| S2 | 1656.87 | -71.43 | -4.13% |
| S3 | 1675.43 | -52.87 | -3.06% |
| S4 | 1701.87 | -26.43 | -1.53% |
CORONA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 1694 ~ 1715.1
Trading Inside opening range
Corona Remedies Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Corona Remedies Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Corona Remedies Ltd stood at 46.3% of traded volume, against a 20-day average of 53.4%.
Corona Remedies announcements: results, concalls, ratings, M&A.
Filings Corona Remedies sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Corona Remedies files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 50 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
CORONA Remedies Limited has informed the Exchange about Schedule of Analysts / Investor Conference
Disclosure under SEBI Takeover Regulations
Dr. Kirtikumar L. Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Analysts/Institutional Investor Meet/Con. Call Updates
CORONA Remedies Limited has informed the Exchange about Intimation of Non-Deal Roadshow
Analysts/Institutional Investor Meet/Con. Call Updates
CORONA Remedies Limited has informed the Exchange about Intimation for Non-Deal Roadshow
Press Release
CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Receipt of EU-GMP…
Investor decks & rating reports.
Corona Remedies dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Corona Remedies has declared, sequenced by announce and record date.
Corona Remedies corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Corona Remedies Ltd: business, sector, key facts.
What Corona Remedies Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Corona Remedies Ltd is a listed Indian equity, listed as NSE: CORONA, BSE: 544644.
Corona Remedies Ltd
Questions investors ask about Corona Remedies Ltd (CORONA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Corona Remedies Ltd (CORONA)?
The current share price of Corona Remedies Ltd (CORONA) is ₹1,728.3. Today, the stock has gained by ₹45.10 (2.68%), trading in a range of ₹1,694 to ₹1,739. The stock opened at ₹1,715 with a trading volume of 8,660 shares.
02Is Corona Remedies Ltd stock a good investment for long-term?
Corona Remedies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,602.71 crores, P/E ratio of 58.80, ROE of 27.60%, and ROCE of 31.50%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Corona Remedies Ltd stock?
The 52-week high price of Corona Remedies Ltd (CORONA) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,728.3, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Corona Remedies Ltd stock at the current price?
Whether to buy Corona Remedies Ltd stock at ₹1,728.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 58.80 and P/B ratio of 0.00. Today's performance shows a gain of 2.68%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Corona Remedies Ltd and when is the next dividend?
Corona Remedies Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,728.3, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Corona Remedies Ltd?
Corona Remedies Ltd's key financial metrics include: P/E Ratio: 58.80, P/B Ratio: 0.00, ROE: 27.60%, ROCE: 31.50%, Dividend Yield: 0.00%, EPS: ₹24.40, Book Value: ₹0, and Debt-to-Equity: 0.21. The company's market cap stands at ₹10,602.71 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Corona Remedies Ltd stock performing today in the market?
Corona Remedies Ltd stock opened at ₹1,715 and is currently trading at ₹1,728.3, showing a gain of ₹45.10 (2.68%). The intraday high is ₹1,739 and low is ₹1,694. The trading volume stands at 8,660 shares, indicating moderate market participation today.
08What is the P/E ratio of Corona Remedies Ltd and what does it indicate?
Corona Remedies Ltd has a Price-to-Earnings (P/E) ratio of 58.80, which means investors are willing to pay ₹58.80 for every ₹1 of earnings. With an EPS of ₹24.40, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Corona Remedies Ltd (CORONA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy